Bringing patients closer to clinical research improves patient engagement and outcomes. Patients get access to the latest research and treatment opportunities, and clinical research can decrease the overall cost of care for both the patient and the health system, as well.
But reaching patient populations can be a very real challenge. Elligo tackles that challenge head on by going directly into communities to connect with the practices and patients, decreasing barriers to access and participation.
Up to 80% of trials fail to meet their enrollment objectives. When a leading HPV vaccine pharmaceutical company was struggling to enroll participants in a study, our data science specialists used the IntElligo Research Stack™ platform to quickly identify qualified patients – and helped the study successfully meet its enrollment goals.
Putting Healthcare IoT in the Home
As technologies advance, helping providers stay connected to patients through remote monitoring using the Internet of Things (IoT) is becoming more realistic. In this PharmaVOICE article, however, Rebecca Kush, Ph.D., chief scientific officer at Elligo, discusses some of the risks related to insurance and advises that IoT must prove its value before being implemented as a solution for healthcare needs.
The Uptick in AI Use Will Bring Pharma Into the Future Faster
In this PharmaVOICE article, industry experts weigh in on the potential impact of artificial intelligence (AI) in 2020. Rebecca Kush, Ph.D., chief scientific officer at Elligo, gives her perspective, which includes advice to ensure the quality and variety of the underlying data that powers it. She also shares her opinion on where AI would be most valuable: on larger studies, safety or post-marketing studies, and feasibility studies based on real-world data.
The separation of clinical research and patient care has deep roots, but new demands to decrease cost and increase quality have both sides looking for new solutions. Collaboration brings one solution, increasing the volume of patients participating in clinical research and improving the kind of care that can be offered in many communities and to a wide breadth of patient populations. Learn more about the benefits — including the cost, speed, and quality of trials — in this article co-authored by Alycia Rose James, an independent healthcare consultant, and Mary Costello, Vice President, Training and Development at Elligo Health Research.
Disruption of old processes by new technologies may be a positive concept and may stimulate innovation; however, we must acknowledge that disruption is not what patients seek, especially when considering their healthcare, their well-being, and their livelihood. Learn why disruption is occurring and the approaches that must be taken to eliminate this disruption for patients and other stakeholders to smooth the path toward better participation in this Applied Clinical Trials article co-authored by Rebecca Kush, Ph.D., scientific innovation officer, and John Potthoff, Ph.D., CEO at Elligo Health Research.
Elligo is proud to announce that we’re being recognized as one of Austin’s most innovative homegrown companies on the 2019 Austin A-List! We were recognized for our work to provide all patients with access to clinical research as a care option by reaching out to physicians and patients who otherwise would not be able to participate in clinical research. Through our novel IntElligo Research Stack™ clinical technology and Goes Direct® approach, we accelerate the development of pharmaceutical, biotechnology, medical device, and diagnostic products. See the full 2019 Austin A-List at https://www.austinchamber.com/blog/austin-chamber-announces-most-innovation-homegrown-companies-of-2019.
Learn how novel innovations in technology and infrastructure can preserve the physician-patient relationship in this Contract Pharma article by Rebecca Kush, Ph.D., scientific innovation officer at Elligo Health Research.
What advantages do global data standardization bring to clinical research and the patients it serves? Learn how fine-tuning regulatory submissions and improving policymaking are expected to help ensure the meaningful exchange of trial data in this Applied Clinical Trials article co-authored by Rebecca Kush, Ph.D., scientific innovation officer at Elligo Health Research.
The Wall Street Journal interviewed John Potthoff, Ph.D., CEO at Elligo Health Research, about Elligo’s model that makes it easier for physician practices to participate in clinical research. Elligo is one of several startups mentioned that are working in significant ways to improve clinical research.
John Potthoff, Ph.D., CEO at Elligo Health Research, was interviewed for The Silicon Review’s “50 Innovative Companies to Watch 2018.” In his interview, Potthoff explained how Elligo’s work to streamline patient-oriented research is helping improve clinical research outcomes and close the gap between research and health care.